Odyssey Therapeutics is targeting a valuation of up to $809.9 million in its U.S. initial public offering. The filing signals continued IPO activity in healthcare and biotech, but the article provides no pricing, proceeds, or operating performance details. Overall impact is likely limited to the company and comparable biotech listings.
Odyssey Therapeutics is targeting a valuation of up to $809.9 million in its U.S. initial public offering. The filing signals continued IPO activity in healthcare and biotech, but the article provides no pricing, proceeds, or operating performance details. Overall impact is likely limited to the company and comparable biotech listings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
